Paper33909232
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ and 17 others. Invest New Drugs, 2021. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Papers, record 33909232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33909232
- Disease
- cancer699 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hydrazines | Major topic |
| Karyopherins | Major topic |
| Neoplasms | Major topic |
| Receptors, Cytoplasmic and Nuclear | Major topic |
| Triazoles | Major topic |
| Active Transport, Cell Nucleus | |
| Adult | |
| Aged | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Dose-Response Relationship, Drug | |
| Female | |
| Humans | |
| Male | |
| Maximum Tolerated Dose | |
| Middle Aged | |
| Topotecan | |
| Exportin 1 Protein |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| UL1 TR003167 | NCATS NIH HHS | United States | UL1TR003167 | PubMed and NIH | NIH RePORTER |
| (1UL1TR003167) | Clinical and Translational Sciences Award (NIH/NCATS) | UL1TR003167 | PubMed and NIH | NIH RePORTER | |
| (P30CA016672) | MD Anderson Cancer Support Grant (NIH-NCI) | P30CA016672 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 34705134 | Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. | https://conductscience.org/library/papers/34705134 |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 2 | 28810913 | Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. | Breast Cancer Res | 2017 | https://conductscience.org/library/papers/28810913 | PubMed |
| 3 | 29487219 | A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. | Oncologist | 2018 | https://conductscience.org/library/papers/29487219 | PubMed |
| 4 | 22773955 | The CRM1 nuclear export protein in normal development and disease. | Int J Biochem Mol Biol | 2012 | https://conductscience.org/library/papers/22773955 | PubMed |
| 5 | 24755012 | Clinical translation of nuclear export inhibitors in cancer. | Semin Cancer Biol | 2014 | https://conductscience.org/library/papers/24755012 | PubMed |
| 6 | 9384386 | CRM1 is responsible for intracellular transport mediated by the nuclear export signal. | Nature | 1997 | https://conductscience.org/library/papers/9384386 | PubMed |
| 7 | 25716206 | Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. | Blood | 2015 | https://conductscience.org/library/papers/25716206 | PubMed |
| 8 | 19574837 | Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. | Neurosurgery | 2009 | https://conductscience.org/library/papers/19574837 | PubMed |
| 9 | 19082467 | The expression of CRM1 is associated with prognosis in human osteosarcoma. | Oncol Rep | 2009 | https://conductscience.org/library/papers/19082467 | PubMed |
| 10 | 27487856 | XPO1, therapeutic … and prognostic target in sarcomas. | Oncoscience | 2016 | https://conductscience.org/library/papers/27487856 | PubMed |
| 11 | 27733172 | CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. | J Hematol Oncol | 2016 | https://conductscience.org/library/papers/27733172 | PubMed |
| 12 | 30112106 | Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. | Oncotarget | 2018 | https://conductscience.org/library/papers/30112106 | PubMed |
| 13 | 22833564 | NESdb: a database of NES-containing CRM1 cargoes. | Mol Biol Cell | 2012 | https://conductscience.org/library/papers/22833564 | PubMed |
| 14 | 20003838 | Prognostic value of CRM1 in pancreas cancer. | Clin Invest Med | 2009 | https://conductscience.org/library/papers/20003838 | PubMed |
| 15 | 18991627 | CRM1-mediated nuclear export of proteins and drug resistance in cancer. | Curr Med Chem | 2008 | https://conductscience.org/library/papers/18991627 | PubMed |
| 16 | 31052304 | XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. | J Clin Med | 2019 | https://conductscience.org/library/papers/31052304 | PubMed |
| 17 | 20651182 | Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. | AJR Am J Roentgenol | 2010 | https://conductscience.org/library/papers/20651182 | PubMed |
| 18 | 30996012 | A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. | Oncologist | 2019 | https://conductscience.org/library/papers/30996012 | PubMed |
| 19 | 25316614 | Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. | J Hematol Oncol | 2014 | https://conductscience.org/library/papers/25316614 | PubMed |
| 20 | 31822399 | Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. | Gynecol Oncol | 2020 | https://conductscience.org/library/papers/31822399 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40313327 | Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle? | J Immunother Precis Oncol | 2025 | https://conductscience.org/library/papers/40313327 | PubMed |
| 39816915 | Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial. | J Immunother Precis Oncol | 2025 | https://conductscience.org/library/papers/39816915 | PubMed |
| 38783482 | The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials. | Clin Transl Med | 2024 | https://conductscience.org/library/papers/38783482 | PubMed |
| 35941226 | The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/35941226 | PubMed |
| 34944778 | Therapeutic Targeting of Exportin-1 in Childhood Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944778 | PubMed |
| 34559346 | Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. | Invest New Drugs | 2022 | https://conductscience.org/library/papers/34559346 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
| XPO1 | 7514 | PubTator's text mining | https://conductscience.org/library/genes/7514 | NCBI Gene |
Drugs17
The drugs whose trials, in the Pipelines release, list the paper.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33909232
GET https://conductscience.org/api/papers/v1/33909232/references?page=2